Skip to content
DataLookout
Menu

H951-MENONCT07751029

Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 31 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 22 words
    • Primary and study completion pushed from Oct 2026 to Dec 2026
    • Start date changed from estimate of Sep 21, 2026 to Oct 26, 2026
  2. Notable Recruitment opened
    • Primary completion date: Sep 2026 to Oct 2026
    • Start date: Aug 2026 to Sep 21, 2026
    • Site details revised
    v3
  3. Minor Site contact updated
    • Collaborators revised (2)
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Vasomotor Symptom Episode
Timeframe: Baseline to Day 30

Secondary (1)

Sleep

Arms and interventions

Haelan 951Experimental

Participants will receive Haelan 951, a fermented soy conventional food product, for 30 consecutive days. Following an in-person screening and baseline visit, participants will complete the study using a decentralized, site-anchored hybrid model with electronic patient-reported outcome (ePRO) assessments, wearable device monitoring, and scheduled remote follow-up.

Dietary supplements: Haelan 951

Sites

1 site in 1 country

  • Spectrum Clinical ResearchKansas City, Missouri, United States